Several abnormalities of cytokines have been shown to occur in systemic scleroderma; however their correlation with clinical parameters is controversial. Since serum concentrations of cytokine receptors have been shown to correlate with inflammatory processes, including systemic sclerosis, the aim of our study was to compare serum concentrations of TNFα receptor type 1 with the concentrations of soluble intercellular adhesion molecule-1 (sICAM-1), soluble interleukin-2 receptor (sIL-2R) and aminoterminal propeptide of procollagen type III (PIII NP). The findings were correlated with the clinical parameters and antibody patterns, and with the disease severity. Serum samples were studied with the use of enzyme-linked immunosorbent assay (ELISA) or radioimmunoassay (RIA) for sTNFα R1, sICAM-1, sIL-2R and PIII NP. The series comprised 36 patients with systemic scleroderma: 13 with diffuse variety and 23 with limited variety, and 7 with Raynaud’s disease. Healthy volunteers (n = 25) were chosen from doctors and/or other laboratory staff. Increased levels of sTNFα-receptor type 1 were found in 77% of patients with diffuse variety and in only 30% of patients with limited form. Increased serum concentrations in patients with diffuse scleroderma and limited variety were found for sICAM-1 54% and 65%, for sIL-2R 46% and 15%, and for PIIINP 77% and 50%, respectively. There were significant correlations between serum levels of sTNFα-receptor type 1 and PIIINP (r = 0.653, p < 0.0001), and sTNFα-receptor type 1 and sIL-2R (r = 0.625, p < 0.0001), but not between sTNFα-receptor type 1 and sICAM-1 (r = 0.127, p < 0.526). Clinical analysis revealed that serum concentrations of sTNFα-R1 seem to correlate best with the severity of the disease and, as the only parameter, correlated with lung involvement. The study showed that, in addition to recognized parameters of scleroderma severity (IL-2R, PIIINP), a new important marker appears to be sTNFα-receptor type 1. Key words: cytokine receptors; disease severity; scleroderma.

( Accepted November 26, 1998.)

Acta Derm Venereol 1999; 79: 207–210.

S. Majewski MD, Department of Dermatology and Venereology, Warsaw School of Medicine, Koszykowa PL-82A02-008, Warsaw, Poland.

Patients with systemic sclerosis (SSc) show, in addition to tissue fibrosis, a variety of distinct immunological and vascular abnormalities (1, 2). The process of fibrosis in SSc seems to be a secondary phenomenon and may result from migration of peripheral blood mononuclear cells (PBMC) into the perivascular spaces, leading to cell activation, production of various proinflammatory cytokines (3–5) and upregulation of some adhesion molecules involved in the enhancement of immune reactions (6–8).

Evaluation of serum levels of interleukins (IL-1, IL-2, IL-4, IL-6), interferon gamma (IFNγ) and TNFα revealed some abnormalities, but no evident clinical correlations were found between cytokine levels and the extent or severity of organ involvement (3–5). Recently, however, it was reported that increased levels of TNFα may reflect the inflammatory stage and also the extent of internal involvement (9).

One of the most important mechanisms controlling serum levels of cytokines and their biological activity is the generation of soluble forms of cytokine receptors, whose concentrations in body fluids could also serve as parameters of inflammation and immune system involvement. In SSc, serum levels of sIL-2R were found to be a more sensitive parameter than IL-2 concentrations, and serum levels of sIL-2R correlated with disease severity, mortality and recent disease onset (10, 11). Increased levels of TNFαR were reported in a single study on a small cohort of SSc patients, however the prognostic value was not evaluated and no correlations with type of SSc and visceral involvement were shown (12). In addition to cytokine receptors, soluble forms of various adhesion molecules involved in inflammatory processes could be detected in the sera of SSc patients, and this may reflect vascular and immune involvement (6, 13, 14).

The aim of this study was to examine serum concentrations of TNFα-receptor type 1 (sTNFα-R1), as related to soluble ICAM-1 (sICAM-1), sIL-2R, and amino-terminal propeptide of procollagen (PIII NP) in 36 patients with SSc, and correlate this with the clinical parameters of the disease severity. In addition, 7 patients with Raynaud’s disease and 25 healthy individuals were studied as controls.

MATERIAL AND METHODS

Patients

All patients with SSc in this study fulfilled the criteria of the American Rheumatism Association (15). Diffuse scleroderma (dSSc) was diagnosed if indurations of the skin involved the face, extremities and central trunk. Limited scleroderma (lSSc) was diagnosed according to criteria described by Le Roy et al. (16) in patients with skin changes confined to the face and forearms. The dSSc group comprised 13 individuals (mean age 51.7 years, range 35–66 years, 6 males and 7 females). The lSSc group comprised 23 patients (mean age 53.2 years, range 21–71 years, 2 males and 21 females). The group of patients with Raynaud’s disease comprised 7 individuals (mean age 38.9 years, range: 17–52 years, 2 males and 5 females). As control, sera from 25 adult healthy volunteers were studied. Informed consent was obtained for all patients and controls.

In all patients the internal organ involvement was evaluated. Patients were considered to have oesophageal involvement if they had symptoms of oesophagus dysmotility on radiography or scintigraphy. Lung involvement was assessed by X-ray examination and lung func-
Evaluation of serum levels of sTNF-α, sIL-2R, sICAM-1 and PIIINP in patients with SSc and Raynaud’s disease (RD)

| Groups | Parameters | sTNF-α-R1 mean ± D (pg/ml) | sIL-2-R mean ± SD (U/ml) | sICAM-1 mean ± SD (ng/ml) | PIIINP mean ± D (mcg/l) |
|--------|------------|---------------------------|--------------------------|--------------------------|-------------------------|
| dSSc   | 1771 ± 769abc | 1592 ± 1167abc | 389 ± 119a | 6.0 ± 1.5abc |
| ISSc   | 1283 ± 250abc | 935 ± 504abc | 367 ± 125c | 4.5 ± 1.4abc |
| RD     | 994 ± 229 0% | 798 ± 796 14% | 228 ± 56 0% | +0.5 14% |
| Controls | means 820 ± 220 | 720 ± 112 | 207 ± 63 | 3.01 ± 0.75 |
|        | normal ranges 380 – 1260 | 496 – 944 | 121 – 333 | 1.5 – 4.5 |

*aSignificantly different from the control,.

bSignificantly different from ISSc, as assessed by Student’s t-test.

The normal ranges, i.e. cut off values were based on the data of 25 healthy control sera (mean ± 2 SD).

| Percentage and numbers of patients with increased serum levels (relates to all patients groups). |

RESULTS

None of the 25 control sera from healthy donors tested showed significantly increased or decreased values for sTNF-α-R1, sIL-2R, sICAM-1 and PIIINP. The mean values for sTNF-α-R1, sIL-2R, sICAM-1 and PIIINP in healthy individuals were: 820 ± 220 pg/ml; 720 ± 112 U/ml; 207 ± 63 ng/ml; and 3.01 ± 0.75 mcg/l, respectively.

Serum levels of sTNF-α-R1 were found to be significantly higher in patients with dSSc than in the controls (Table I). The mean value of sTNF-α-R1 concentration in serum of patients with dSSc was significantly higher than in patients with ISSc (p < 0.01). Individual levels of sTNF-α-R1 were significantly increased in 10/13 (77%) patients with dSSc, in 6/20 (30%) with ISSc and in 0/7 (0%) patients with Raynaud’s disease.

Serum concentrations of sIL-2R were found to be higher in patients with dSSc than in the controls. The mean value of sIL-2R concentration in serum of patients with dSSc was significantly higher than in serum of patients with ISSc (p < 0.03) (Table I). The levels of sIL-2R were significantly increased in 6/13 (46%) patients with dSSc, much less in ISSc, 3/20 (15%), and in only 1 patient with Raynaud’s disease.

Serum levels of sICAM-1 were found to be higher in patients with dSSc than in the control. Mean values of sICAM-1 concentration in sera of patients with dSSc did not differ from those of patients with ISSc (Table I). Individual levels of sICAM-1 were significantly increased in 7/13 (54%) patients with dSSc and in 15/23 (65%) with ISSc, but not in patients with Raynaud’s disease.

Mean values of PIIINP concentrations in serum of patients with dSSc were significantly higher than in the patients with ISSc (p < 0.008) (Table I). Individual concentrations of PIIINP were significantly increased in 10/13 (77%) patients with dSSc and in a high proportion of patients with ISSc (9/18, 50%). One patient with Raynaud’s disease also had an increased level of serum PIIINP.

Linear regression analysis of the data showed significant correlations between serum concentrations of sTNF-α-R1 and sIL-2R (p = 0.001) as well as PIIINP (p = 0.001) and PIIINP (p = 0.001) and sIL-2R (p = 0.002), whereas there was no correlation between levels of sICAM-1 and other parameters.

Serum levels of TNF-α-R1 showed the best clinical correlations with skin, muscle and lung involvement (Table II). Increased TNF-α-R1 serum concentration was the only parameter which significantly correlated with the lung disease in SSc. Increased values of all parameters studied, except for ICAM-1, i.e. sTNF-α-R1, sIL-2R and PIIINP, also correlated with muscle involvement and central skin sclerosis. There was no correlation between these parameters and arthralgia, duration of Raynaud’s phenomenon and duration of skin sclerosis. Concentrations of sTNF-α-R1, sIL-2R, sICAM-1 and PIIINP did not correlate with titres and types of ANA (data not shown).
DISCUSSION

This study on selected laboratory parameters reflecting immune, fibrotic and inflammatory vascular processes in patients with SSc confirmed previous findings on increased levels of sIL-2R (6, 11), sICAM-1 (9, 13, 14) and PIIINP (21 – 23) in these patients. The highest mean values of all parameters (except for sICAM-1) were found in patients with dSSc, significantly different from the mean values in patients with lSSc. Most importantly, we found a significant increase of sTNF-RI in a high proportion of sera from patients with SSc, especially in dSSc. Increased serum levels of TNF-α type I and II receptors were reported in SSc patients in a single study, and these authors found a significant correlation between the concentrations of the two types of receptors (12). This was the reason for studying only one type of TNF-α receptor (R1), but, in addition, we correlated its levels with other parameters of inflammation and clinical data.

Analysis of individual patients' data revealed that serum levels of both sTNF-RI and PIIINP were most frequently increased in dSSc (77% of cases), compared with the concentrations of sIL-2R and sICAM-1. In our series, increased levels of sIL-2R appeared to be a less sensitive parameter of disease severity than did the concentrations of sTNF-RI and PIIINP. In lSSc, increased concentrations of sTNF-RI and sIL-2R were about three-fold less frequently detected than in dSSc, whereas increased serum levels of sICAM-1 were found with equal frequency in dSSc and lSSc. There was also no correlation between serum levels of sICAM-1 and extent of skin involvement. Similar data were reported by Denton et al. (24) who found that sICAM-1 level did not reflect clinical changes in SSc patients. This would suggest that sICAM-1 is not only related to fibrosis, in spite of its pronounced expression on SSc fibroblasts (6). The soluble ICAM-1 might also be released from activated endothelial cells and mononuclear cells expressing this molecules (6, 14).

In contrast, serum levels of sTNF-RI, sIL-2R and PIIINP correlated significantly with each other. No correlation of TNF-α-R and IL-2R levels was found by Heilig et al. (12), who suggested that these could be independent parameters. However, in our study on a large cohort of SSc patients, all these parameters correlated significantly between themselves but, most importantly, with the extent of cutaneous sclerosis (central skin involvement). It should be stressed that levels of sTNF-RI showed better correlations with lung involvement than did PIIINP. Expression of TNF-α-RI is not restricted to lymphocytes, but is also detected on epithelial cells and macrophages (25). This could explain the positive correlation of increased serum level of sTNF-RI with lung involvement in which the activation of macrophages and possibly also of epithelial alveolar cells is of great importance for development of the interstitial fibrosis.

Disparate results were reported for the levels of TNF-α in the sera of SSc patients (4, 9). However, these authors did not evaluate serum concentrations of sTNF-RI, which, as an inhibitor of TNF-α, could substantially affect the levels of TNF-α.

Although the pathogenic significance of soluble cytokine receptors is not known, it is conceivable that high levels of soluble TNF-αR, by formation of complexes with TNF-α, may inhibit the biological activity of endogeneous TNF-α, which is known to decrease collagen synthesis and stimulate collagenase (26, 27). In this way, TNF-αR could contribute to the enhancement of the fibrotic process. Another possibility is that the increased level of TNF-αR is only reflecting cytokine activation in the immunologically induced fibrosis. Thus, in addition to recognized parameters of SSc severity (IL-2R, PIIINP), a new important marker appears to be sTNF-RI. All three parameters of inflammation and fibrosis might reflect the clinical condition and could be helpful in prognostication and monitoring the therapies. In this study TNF-αRI proved to be the most sensitive indicator of severity of SSc.

ACKNOWLEDGEMENT

The study was supported by a grant 4 PO5 B04110 from the Polish Committee for Scientific Research.

REFERENCES

1. White B. Immune abnormalities in systemic sclerosis. Clin Dermatol 1994; 12: 349 – 359.
2. Krieg T, Meurer M. Systemic scleroderma. J Am Acad Dermatol 1988; 18: 457 – 481.
3. Degiannis D, Seibold J, Czarnecki M, Raskova J, Raska K. Soluble and cellular markers of immune activation in patients with systemic sclerosis. Clin Immunol Immunopathol 1990; 56: 259 – 270.
4. Needleman BW, Wigley FM, Stair RW. Interleukin-1, interleukin-2, interleukin-4, interleukin-6, tumor necrosis factor-α, and inter.

---

Table II. Correlations of clinical and laboratory findings in patients with SSc

| Clinical parameters          | Laboratory parameters |
|-----------------------------|-----------------------|
|                            | sTNF-RI | sIL2-R | sICAM-1 | PIIINP |
| R (duration of Raynaud’s phenomenon) | ns      | ns      | ns      | ns      |
| S (duration of skin sclerosis)       | ns      | ns      | ns      | ns      |
| Less than 2 year interval between R and S | p = 0.01 | ns      | ns      | ns      |
| Central skin involvement         | p = 0.01 | p = 0.03 | ns      | p = 0.007 |
| Arthralgia                      | ns      | ns      | ns      | ns      |
| Internal organ involvement:     |         |         | ns      |         |
| Oesophagus                      | ns      | ns      | ns      | ns      |
| Lungs                          | p = 0.006 | ns      | ns      | ns      |
| Heart                          | ns      | ns      | ns      | ns      |
| Muscles                        | p = 0.001 | p = 0.01 | ns      | p = 0.001 |

The statistical significance was determined by chi² test.
ns = non-significant.
feron-α levels in sera from patients with scleroderma. Arthritis Rheum 1992; 35: 67 – 72.

5. Fagundus DM, LeRoy EC. Cytokines and systemic sclerosis. Clin Dermatol 1994; 12: 397 – 406.

6. Majewski S, Hunzelmann N, Johnson JP, Jung JC, Mauch C, Ziegler-Heitbrock Wl, et al. Expression of intercellular adhesion molecule-1 (ICAM-1) in the skin of patients with systemic sclerosis. J Invest Dermatol 1991; 97: 667 – 671.

7. Gruschwitz M, von den Driesch P, Kellner I, Hornstein OP, Sterry W. Expression of adhesion proteins involved in cell-cell and cell-matrix interactions in the skin of patients with progressive systemic sclerosis. J Am Acad Dermatol 1992; 27: 169 – 177.

8. Koch AE, Kronfeld-Harrington LB, Szekanecz Z, Cho MM, Haines GK, Harlow LA, et al. In situ expression of cytokines and cellular adhesion molecules in the skin of patients with systemic sclerosis. Pathobiology 1993; 61: 239 – 246.

9. Bruns M, Haustein UF, Hoffmann Ch, Herrman K. Serum levels of soluble IL-2 receptor, soluble ICAM-1, TNF-alpha, interleukin-4 and interleukin-6 in scleroderma. J Eur Acad Dermato Venereol 1997; 8: 222 – 228.

10. Degiannis D, Seibold JR, Czarnecki M, Raskova J, Raska KJr. Soluble interleukin-2 receptor, soluble ICAM-1, TNF-alpha, interleukin-4 and interleukin-6 in scleroderma. J Eur Acad Dermato Venereol 1997; 8: 222 – 228.

11. Clements PJ, Peter JB, Agopian MS. Elevated serum levels of soluble IL-2 receptor, interleukin-2 receptor, interleukin 2 and neopterin in diffuse and limited scleroderma: Effect of chlorambucil. J Rheumatol 1990; 17: 908 – 910.

12. Heilig B, Fiehn C, Brockhaus M, Brockhaus M, Gallati H, Pezzutto A, et al. Evaluation of soluble tumor necrosis factor (TNF) receptors and TNF receptor antibodies in patients with systemic lupus erythematosus, progressive systemic sclerosis, and mixed connective tissue diseases. J Clin Immunol 1993; 13: 321 – 328.

13. Carson CW, Beall LD, Hunder GG, Johnson CM, Newman W. Serum ELAM-1 is increased in vasculitis, scleroderma, and systemic lupus erythematosus. J Rheumatol 1993; 20: 809 – 814.

14. Gruschwitz MS, Hornstein OP, von den Driesch P. Correlation of soluble adhesion molecules in the peripheral blood of scleroderma patients with their in situ expression and with disease activity. Arthritis Rheum 1995; 38: 184 – 189.

15. Subcommittee for scleroderma criteria of the ARA. Diagnostic and Therapeutic Criteria Committee. Preliminary criteria for the classification of systemic sclerosis (scleroderma). Arthritis Rheum 1980; 23: 581 – 590.

16. Le Roy E, Black C, Fleischmajer R, Jablonska S, Krieg T, Medsger TA, et al. Scleroderma (systemic sclerosis). Classification, subsets and pathogenesis. J Rheumatol 1988; 15: 202 – 205.

17. Chorzelski TP, Jablonska S, Beutner EH, Blaszczyk M, Jarzabek-Chorzelska M, Kenka D, et al. Anticentromere antibody: an immunological marker of a subset of systemic sclerosis. Br J Dermatol 1985; 113: 381 – 389.

18. Jarzabek-Chorzelska M, Blaszczyk M, Jablonska S, Chorzelski TP, Kumar V, Beutner EH. ScI 70 antibody: a specific marker of systemic sclerosis. Br J Dermatol 1986; 115: 393 – 397.

19. Jablonska S, Blaszczyk M, Chorzelski TP, Jarzabek-Chorzelska M, Kumar V, Beutner EH. Clinical relevance of immunologic findings in scleroderma. Clin Dermatol 1993; 10: 407 – 421.

20. Majewski S, Skiedziewska A, Mikaela B, Jablonska S, Blaszczzyk M, Mejewski S, Rudnicka M. Scleroderma and dermatomyositis. In: Kanitakis J, Vassileva S, Woodley D, editors. Diagnostic immunohistochemistry of the skin. An illustrated text. London: Chapman and Hall Medical, 1998: 157 – 172.

21. Krieg T, Langer G, Gerstheimer H, et al. Type III collagen aminopeptide levels in serum of patients with progressive systemic sclerosis. J Invest Dermatol 1986; 87: 788 – 791.

22. Majewski S, Skiedziewska A, Mikaela B, Jablonska S, Blaszczzyk M, Mejewski S, Rudnicka M. Scleroderma and dermatomyositis. In: Kanitakis J, Vassileva S, Woodley D, editors. Diagnostic immunohistochemistry of the skin. An illustrated text. London: Chapman and Hall Medical, 1998: 157 – 172.

23. Carmona D, Seibold JR, Czarnecki M, Raskova J, Raska KJr. Soluble interleukin-2 receptor, soluble ICAM-1, TNF-alpha, interleukin-4 and interleukin-6 in scleroderma. J Eur Acad Dermato Venereol 1997; 8: 222 – 228.

24. Degiannis D, Seibold JR, Czarnecki M, Raskova J, Raska KJr. Soluble interleukin-2 receptors in patients with systemic sclerosis. Arthritis Rheum 1990; 33: 375 – 380.

25. Clements PJ, Peter JB, Agopian MS. Elevated serum levels of soluble IL-2 receptor, interleukin-2 receptor, interleukin 2 and neopterin in diffuse and limited scleroderma: Effect of chlorambucil. J Rheumatol 1990; 17: 908 – 910.

26. Heilig B, Fiehn C, Brockhaus M, Brockhaus M, Gallati H, Pezzutto A, et al. Evaluation of soluble tumor necrosis factor (TNF) receptors and TNF receptor antibodies in patients with systemic lupus erythematoses, progressive systemic sclerosis, and mixed connective tissue diseases. J Clin Immunol 1993; 13: 321 – 328.

27. Carson CW, Beall LD, Hunder GG, Johnson CM, Newman W. Serum ELAM-1 is increased in vasculitis, scleroderma, and systemic lupus erythematosus. J Rheumatol 1993; 20: 809 – 814.

28. Gruschwitz MS, Hornstein OP, von den Driesch P. Correlation of soluble adhesion molecules in the peripheral blood of scleroderma patients with their in situ expression and with disease activity. Arthritis Rheum 1995; 38: 184 – 189.

29. Subcommittee for scleroderma criteria of the ARA. Diagnostic and Therapeutic Criteria Committee. Preliminary criteria for the classification of systemic sclerosis (scleroderma). Arthritis Rheum 1980; 23: 581 – 590.

30. Le Roy E, Black C, Fleischmajer R, Jablonska S, Krieg T, Medsger TA, et al. Scleroderma (systemic sclerosis). Classification, subsets and pathogenesis. J Rheumatol 1988; 15: 202 – 205.

31. Chorzelski TP, Jablonska S, Beutner EH, Blaszczyk M, Jarzabek-Chorzelska M, Kenka D, et al. Anticentromere antibody: an immunological marker of a subset of systemic sclerosis. Br J Dermatol 1985; 113: 381 – 389.

32. Jarzabek-Chorzelska M, Blaszczyk M, Jablonska S, Chorzelski TP, Kumar V, Beutner EH. ScI 70 antibody: a specific marker of systemic sclerosis. Br J Dermatol 1986; 115: 393 – 397.

33. Jablonska S, Blaszczyk M, Chorzelski TP, Jarzabek-Chorzelska M, Kumar V, Beutner EH. Clinical relevance of immunologic findings in scleroderma. Clin Dermatol 1993; 10: 407 – 421.

34. Majewski S, Skiedziewska A, Mikaela B, Jablonska S, Blaszczzyk M, Mejewski S, Rudnicka M. Scleroderma and dermatomyositis. In: Kanitakis J, Vassileva S, Woodley D, editors. Diagnostic immunohistochemistry of the skin. An illustrated text. London: Chapman and Hall Medical, 1998: 157 – 172.

35. Carmona D, Seibold JR, Czarnecki M, Raskova J, Raska KJr. Soluble interleukin-2 receptor, soluble ICAM-1, TNF-alpha, interleukin-4 and interleukin-6 in scleroderma. J Eur Acad Dermato Venereol 1997; 8: 222 – 228.

36. Degiannis D, Seibold JR, Czarnecki M, Raskova J, Raska KJr. Soluble interleukin-2 receptors in patients with systemic sclerosis. Arthritis Rheum 1990; 33: 375 – 380.

37. Clements PJ, Peter JB, Agopian MS. Elevated serum levels of soluble IL-2 receptor, interleukin-2 receptor, interleukin 2 and neopterin in diffuse and limited scleroderma: Effect of chlorambucil. J Rheumatol 1990; 17: 908 – 910.